 |
|
Recurrence of Hepatocellular Carcinoma Following Liver Transplantation—Invited Critique
Samuel D. Kaffenberger, BS;
J. Wallis Marsh, MD
Arch Surg. 2008;143(2):188.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
The review by Zimmerman et al is important and timely in furthering our awareness of deficiencies in the current staging and allocation system for liver transplantation in the presence of HCC. While there is a consensus within the transplant community that the current pTNM staging system (and therefore the United Network for Organ Sharing and Milan criteria, which are based on this system) is not predictive of HCC recurrence after liver transplantation, little has been done to rectify the situation.
Put succinctly, the most demanding argument for change to current policy is that HCC is the only cancer for which, when diagnosed in its earliest and most curable stage (stage I), a biopsy is deferred and the patient is required to wait for tumor growth and possible spread before being offered potentially curative treatment (ie, liver transplantation; excluding the option of living-donor . . . [Full Text of this Article]
AUTHOR INFORMATION
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Recurrence of Hepatocellular Carcinoma Following Liver Transplantation: A Review of Preoperative and Postoperative Prognostic Indicators
Michael A. Zimmerman, R. Mark Ghobrial, Myron J. Tong, Jonathan R. Hiatt, Andrew M. Cameron, Johnny Hong, and Ronald W. Busuttil
Arch Surg. 2008;143(2):182-188.
ABSTRACT
| FULL TEXT
|
